Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Q1 2024 Earnings Presentation
11 slides from Staar Surgical's earnings presentation, May 7, 2024
Slide 1: 1Q 2024 Earnings Call Supplement
NASDAQ: STAA 1Q 2024 Earnings Call Supplement MAY 7, 2024 Exhibit 99.2
Slide 2: Conference Call and Webcast Speakers, Investor Contact
02 Conference Call and Webcast Speakers Investor Contact TOM FRINZI PATRICK WILLIAMS Chair of the Board, President and CEO Chief Financial Officer WEBCAST ARCHIVE: Audio webcast archive will be available at http://investors.staar.com +1 626.303.7902 x3023 Brian Moore VP, Investor Relations and Corpo
Slide 3: Forward Looking Statements
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adjusted EBITDA, and Adjusted EBITDA per diluted shar
Slide 4: Non-GAAP Financial Measures
To supplement the Company’s financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this presentation and the accompanying tables include certain non-GAAP financial measures, including Adjusted EBITDA. Management uses these non-GAAP financial measures in
Slide 5: First Quarter 2024 Results
First Quarter 2024 Results 1Q24 EARNINGS REPORT ON MAY 7, 2024 OUTLOOK $77.4 M 9% Global ICL Sales Growth $252.1 M Cash, cash equivalents and investments available for sale at Mar 29, 2024 78.9% Gross Margin (2.9%) Operating Margin Net Sales ($3.3 M) GAAP Loss $335 M to $340 M $5.3 M $0.11 Adjusted
Slide 6: First Quarter 2024 & Recent Business Highlights
Achieved three million total implantable collamer® lenses (ICLs) sold in March 2024. >1.5M lCLs have been sold in just the last three years, i.e. fiscal years 2021-2023. First Quarter 2024 & Recent Business Highlights Enhanced commercial focus is yielding positive results Our APAC, EMEA, Americas re
Slide 7: ICL Sales by Geography
ICL Sales by Geography ICL Sales by Region(5) ICL Sales by Country(4,5) 2021 2021 2022 2022 2023 2023 March 31, 2023 March 31, 2023 June 30, 2023 June 30, 2023 September 29, 2023 September 29, 2023 December 29, 2023 December 29, 2023 March 29, 2023 March 29, 2023 Americas(1) EMEA(2) APAC (3) Global
Slide 8: Significant Market Opportunity for EVO ICL
Significant Market Opportunity for EVO ICL™ MYOPIA Today: Every third person in the world STAAR EVO ICL’s near and long-term market opportunity remains exciting and vast, despite any transient noise (previously COVID and now macroeconomic headwinds associated with a normal business cycle). Myopia is
Slide 9: EVO ICL Procedure and Collamer Material Advantage
EVO ICL™ Procedure and Collamer® Material Advantage 200+ Peer-Reviewed ICL Clinical Papers Quick procedure and recovery Additive / Preserves the Cornea 3 Million+ Lenses Sold Does not cause dry eye syndrome 3,4 UV Protection 30+ Year History of Safety and Effectiveness Reversible Lens Implant Sharp,
Slide 10: It's Our Time... It's EVO's Time!
IT’S OUR TIME… IT’S EVO’S TIME!
Slide 11: Reconciliation of Non-GAAP Financial Measures
STAAR Surgical Reconciliation of Non-GAAP Financial Measures Net Income to Adjusted EBITDA (in 000's except for per share data) Unaudited Q1-23 2-23 Q3.23 04-23 2023 Q1-24 2024 Outlook”! Net income - (as reported) $ 2710 $ 6064 $ 4817 $ 7,756 $ 21347 $ (3339) $ - Provision (benefit) for income taxes